# Trade Mark Journal No.2025/038 19 September 2025

## UK00004260068 5 September 2025 (42)

VELOCIVAX

International priority date claimed: 12 March 2025 (United States of America) (99080151)

Class 42
  Pharmaceutical research services, namely, nucleic acid molecule development and nucleic acid molecule delivery development and production; genetic engineering services utilizing a collection of genetic technologies for the production and delivery of immune modulators; scientific, laboratory and medical research in the field of genetic engineering technologies; scientific laboratories performing nucleic acid molecule development and nucleic acid molecule delivery development; scientific research and development, namely, development of nucleic acid molecule and nucleic acid molecule delivery for others.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP